{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:37:04Z","timestamp":1776083824030,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cca.2020.05.035","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:59:20Z","timestamp":1589943560000},"page":"179-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy"],"prefix":"10.1016","volume":"508","author":[{"given":"Haoyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia I.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashlee R.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Q.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"McCaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Millington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2020.05.035_b0005","unstructured":"Neufeld, E.A.M., J, ed. The Metabolic and Molecular Basis of Inherited Disease. The mucopolysaccharidoses, B.A. Scriver C.R., Sly, W.S., Valle, D., 2001, McGraw-Hill, New York, 3421."},{"key":"10.1016\/j.cca.2020.05.035_b0010","unstructured":"L.A. Clarke, Mucopolysaccharidosis Type I, in: GeneReviews((R)), M.P. Adam, et al., (Eds.) Seattle (WA), 1993."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2020.05.035_b0015","first-page":"102","article-title":"Mucopolysaccharidosis type I","volume":"12","author":"Wraith","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"1","key":"10.1016\/j.cca.2020.05.035_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: Management and Treatment Guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.cca.2020.05.035_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1750-1172-8-155","article-title":"Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure","volume":"8","author":"Langereis","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"issue":"13","key":"10.1016\/j.cca.2020.05.035_b0030","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2020.05.035_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2015.10.004","article-title":"Obstructive sleep apnea syndrome after hematopoietic stem cell transplantation in children with mucopolysaccharidosis type I","volume":"116","author":"Moreau","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2020.05.035_b0045","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0929-693X(14)72258-4","article-title":"Principles of therapeutic approaches for mucopolysaccharidoses","volume":"21","author":"Caillaud","year":"2014","journal-title":"Arch. Pediatr."},{"issue":"8","key":"10.1016\/j.cca.2020.05.035_b0050","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.cca.2020.05.035_b0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ymgme.2009.11.008","article-title":"Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis","volume":"99","author":"Mu\u00f1oz-Rojas","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.cca.2020.05.035_b0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2020.05.035_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal enzyme replacement for Hurler syndrome: biomarker association with neurocognitive outcomes","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"issue":"Pt 2","key":"10.1016\/j.cca.2020.05.035_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/000456329803500204","article-title":"Urine analysis in the diagnosis of mucopolysaccharide disorders","volume":"35","author":"Stone","year":"1998","journal-title":"Ann. Clin. Biochem."},{"issue":"3","key":"10.1016\/j.cca.2020.05.035_b0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/metabo4030655","article-title":"Establishment of glycosaminoglycan assays for mucopolysaccharidoses","volume":"4","author":"Tomatsu","year":"2014","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.cca.2020.05.035_b0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-005-0069-y","article-title":"Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses","volume":"28","author":"Tomatsu","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1\u20132","key":"10.1016\/j.cca.2020.05.035_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jchromb.2005.11.047","article-title":"Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical study","volume":"831","author":"Upreti","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"1","key":"10.1016\/j.cca.2020.05.035_b0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2007.05.016","article-title":"Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography\/turbo ionspray ionization tandem mass spectrometry","volume":"368","author":"Oguma","year":"2007","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2009.10.001","article-title":"Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry","volume":"99","author":"Tomatsu","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10545-012-9535-5","article-title":"Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease","volume":"36","author":"de Ruijter","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.cca.2020.05.035_b0105","first-page":"006","article-title":"Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications","volume":"2014","author":"Tomatsu","year":"2014","journal-title":"J. Anal. Bioanal. Tech."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"1\u20132","key":"10.1016\/j.cca.2020.05.035_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgme.2016.09.005","article-title":"Glycosaminoglycans detection methods: Applications of mass spectrometry","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2014.09.009","article-title":"A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses","volume":"114","author":"Zhang","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.cca.2020.05.035_b0125","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"issue":"7\u20138","key":"10.1016\/j.cca.2020.05.035_b0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cca.2012.01.012","article-title":"An improved method for glycosaminoglycan analysis by LC-MS\/MS of urine samples collected on filter paper","volume":"413","author":"Auray-Blais","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"1\u20132","key":"10.1016\/j.cca.2020.05.035_b0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2015.07.005","article-title":"Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I","volume":"116","author":"Dickson","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2020.05.035_b0140","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study","author":"Chen","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2020.05.035_b0145","doi-asserted-by":"crossref","unstructured":"H. Zhang, S. Young, D.S. Millington, Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry, Curr. Protoc. Hum. Genet., (2013), p. Unit 17 12. Chapter 17.","DOI":"10.1002\/0471142905.hg1712s76"},{"issue":"3","key":"10.1016\/j.cca.2020.05.035_b0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jcp.21.3.339","article-title":"Excretion patterns of glycosaminoglycans and glycoproteins in normal human urine","volume":"21","author":"Manley","year":"1968","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2020.05.035_b0155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ymgme.2012.08.008","article-title":"Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening","volume":"107","author":"de Ru","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.cca.2020.05.035_b0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cca.2020.05.035_b0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cca.2020.05.035_b0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpeds.2016.11.036","article-title":"Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management","volume":"182","author":"Clarke","year":"2017","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.cca.2020.05.035_b0175","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"issue":"3","key":"10.1016\/j.cca.2020.05.035_b0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0009-8981(92)90086-6","article-title":"Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behaviour of the protein-polysaccharide complexes in ultrafiltration and chromatographic procedures","volume":"206","author":"Calatroni","year":"1992","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-009-9036-3","article-title":"Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I","volume":"33","author":"Tomatsu","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","article-title":"Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy","volume":"114","author":"Langereis","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10545-012-9538-2","article-title":"Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans","volume":"36","author":"de Ru","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.cca.2020.05.035_b0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00182044","article-title":"Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract","volume":"12","author":"Hurst","year":"1994","journal-title":"World J. Urol."},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/cs0670205","article-title":"A Micropuncture and Renal Clearance Study in the Rat of the Urinary Excretion of Heparin, Chondroitin Sulphate and Metabolic Breakdown Products of Connective Tissue Proteoglycans","volume":"67","author":"Shum","year":"1984","journal-title":"Clin. Sci. (Lond., Engl.: 1979)"},{"issue":"2","key":"10.1016\/j.cca.2020.05.035_b0210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/bj1300597","article-title":"The excretion and degradation of chondroitin 4-sulphate administered to guinea pigs as free chondroitin sulphate and as proteoglycan","volume":"130","author":"Revell","year":"1972","journal-title":"Biochem. J."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120302394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120302394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:55:33Z","timestamp":1757861733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898120302394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"alternative-id":["S0009898120302394"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2020.05.035","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2020.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}